EICHOR
● Completed
Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH
Condition: Homozygous Familial Hypercholesterolemia · Sponsor: LIB Therapeutics LLC
About this study
To compare the safety, tolerability and LDL-C response after 24 Weeks of monthly (every 4 weeks \[Q4W\]) subcutaneous (SC) dosing of LIB003 300 mg with monthly (Q4W) SC dosing of 420 mg evolocumab (Repatha®) in patients with HoFH on stable diet and oral LDL-C-lowering drug therapy
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (12)
| NorthShore University Health System | Evanston, Illinois, United States | — |
| Metabolic & Atherosclerosis Research Center (MARC) | Cincinnati, Ohio, United States | — |
| VMMC & Safdarjung Hospital | Delhi, National Capital Territory of Delhi, India | — |
| CIMS Hospital Pvt. Ltd | Ahmedabad, India | — |
| G.B. Pant Institute of Postgraduate Medical Education & Research | New Delhi, India | — |
| Department of Medicine, Hadassah University Hospital | Jerusalem, Israel | — |
| Rabin Medical Center, Beilinson Hospital, | Petah Tikva, Israel | — |
| Lipid Clinic, Oslo University Hospital | Oslo, Norway | — |
| Carbohydrate and Lipid Metabolism Research Unit | Johannesburg, Gauteng, South Africa | — |
| Division of Lipidology, Department of Medicine University of Cape Town | Cape Town, Western Province, South Africa | — |
| Ege University Medical School | Izmir, Bornova, Turkey (Türkiye) | — |
| Afyonkarahisar Health Sciences University | Afyonkarahisar, Turkey (Türkiye) | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04034485